From the Journals

Tuberculosis Screening Gaps Persist in New DMARD Users


 

TOPLINE:

The rates of screening for latent tuberculosis remain suboptimal among new users of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), with notable variations by medication type and demographic characteristics.

METHODOLOGY:

  • Professional society guidelines recommend screening for tuberculosis before starting treatment with most b/tsDMARDs.
  • In an attempt to estimate the extent of latent tuberculosis screening, researchers combined claims and electronic health record datasets to evaluate 2853 new b/tsDMARD users (mean age, 73 years; 72% women; and 73% non-Hispanic White).
  • The primary analysis focused on assessing the proportion of patients screened for latent tuberculosis in the year before starting a new b/tsDMARD.
  • A sensitivity analysis evaluated the extent of screening within the 3 years preceding the initiation of a new b/tsDMARD.
  • A total of 65.6% of patients received screening for latent tuberculosis in the year before initiating a new b/tsDMARD.
  • Screening rates improved only slightly on expanding the window to 3 years, with 72.9% of patients receiving any tuberculosis screening.
  • When stratified by drug type, over half of new users of Janus kinase inhibitors and nearly 90% of new users of interleukin-17 inhibitors had not received screening.
  • Hispanic patients had lower odds of tuberculosis screening within 1 year than White patients (odds ratio [OR], 0.64; 95% CI, 0.46-0.90), as did those in the highest socioeconomic quartile, compared with the lowest (OR, 0.61; 95% CI, 0.40-0.94).

IN PRACTICE:

“Educational initiatives, team-based care delivery, task shifting, and technological interventions to address observed gaps in patient safety procedures are needed,” the authors wrote.

SOURCE:

The study was led by Eric T. Roberts, PhD, University of California, San Francisco, and published online in Arthritis Care & Research

LIMITATIONS:

The study lacked access to scanned documents or clinical notes, which may have resulted in the omission of a small number of tests that had no Medicare billing. Moreover, the study was restricted to a 3-year lookback period, potentially missing some remote screenings. The findings may have limited generalizability to younger patients or those not dually eligible for Medicare and Medicaid.

DISCLOSURES:

This study was funded by grants from the Agency for Healthcare Research and Quality and the National Institute for Arthritis and Musculoskeletal and Skin Diseases. The authors declared no conflicts of interest.

A version of this article appeared on Medscape.com.

Recommended Reading

What Markers Are Helpful to Diagnose Infection in Tocilizumab Users?
MDedge Rheumatology
FDA Approves 10th Humira Biosimilar, With Interchangeability
MDedge Rheumatology
DMARDs Restore GI Microbiota Balance in RA But Ability to Predict Response Falls Short
MDedge Rheumatology
New Biomarkers Identified to Help Predict Cardiovascular Risk in RA
MDedge Rheumatology
Leflunomide: A Fresh Look at an Old Drug
MDedge Rheumatology
Second FDA-Approved Tocilizumab Biosimilar Has Intravenous, Subcutaneous Formulations
MDedge Rheumatology
RA Outcomes Worsened by Depression and Anxiety, Signaling Need for Multidisciplinary Action
MDedge Rheumatology
AI’s Future and Current Role in Rheumatology
MDedge Rheumatology
No Excess Cancer Risk Seen with Non-TNF Inhibitor Biologics in RA
MDedge Rheumatology
Autoimmunity’s Female Bias and the Mysteries of Xist
MDedge Rheumatology